DalsnaFinance

Revvity $RVTY

Health Care · Health Care Equipment · NYSE/NASDAQ

S&P 500 Russell 1000 Massachusetts
Create a scorecard
$155.25
+4.31 (+2.86%)
As of Oct 20, 2026, 12:59 PM EDT
Price history
Loading chart…

Key facts

52-week range (closes)
$82.26 – $157.36 Lowest close Apr 29, 2026, highest Oct 5, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Fiscal year ends
December Fiscal 2025 ended Dec 28, 2025, from SEC filings
In the S&P 500 since
May 31, 1985 · All S&P 500 changes

Revvity (RVTY) is trading up at $155.25 (+2.86%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Revvity revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$3.83B$1.91B$0FY2016 revenue: $2.12BFY2016 net income: $234.3M · Net margin 11.1%'16FY2017 revenue: $2.26BFY2017 net income: $292.6M · Net margin 13.0%'17FY2018 revenue: $2.78BFY2018 net income: $237.9M · Net margin 8.6%'18FY2019 revenue: $2.88BFY2019 net income: $227.6M · Net margin 7.9%'19FY2020 revenue: $3.78BFY2020 net income: $727.9M · Net margin 19.2%'20FY2021 revenue: $3.83BFY2021 net income: $943.2M · Net margin 24.6%'21FY2022 revenue: $3.31BFY2022 net income: $569.2M · Net margin 17.2%'22FY2023 revenue: $2.75BFY2023 net income: $693.1M · Net margin 25.2%'23FY2024 revenue: $2.76BFY2024 net income: $270.4M · Net margin 9.8%'24FY2025 revenue: $2.86BFY2025 net income: $241.2M · Net margin 8.4%'250%10%20%30%FY2016 net margin: 11.1%FY2017 net margin: 13.0%FY2018 net margin: 8.6%FY2019 net margin: 7.9%FY2020 net margin: 19.2%FY2021 net margin: 24.6%FY2022 net margin: 17.2%FY2023 net margin: 25.2%FY2024 net margin: 9.8%FY2025 net margin: 8.4%
Revvity annual financial statements
FY2016Jan 2017FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Jan 2021FY2021Jan 2022FY2022Jan 2023FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$2.12B$2.26B$2.78B$2.88B$3.78B$3.83B$3.31B$2.75B$2.76B$2.86B
Growth (year over year)+0.5%+6.7%+23.1%+3.8%+31.2%+1.2%−13.5%−16.9%+0.2%+3.7%
Gross profit$1.01B$1.07B$1.34B$1.40B$2.11B$2.43B$1.99B———
Gross margin47.9%47.6%48.3%48.4%55.8%63.6%60.1%———
Operating income$294.6M$295.6M$323.9M$362.0M$867.3M$1.26B$742.7M$300.6M$346.7M$356.6M
Operating margin13.9%13.1%11.7%12.6%22.9%32.9%22.4%10.9%12.6%12.5%
Net income$234.3M$292.6M$237.9M$227.6M$727.9M$943.2M$569.2M$693.1M$270.4M$241.2M
Net margin11.1%13.0%8.6%7.9%19.2%24.6%17.2%25.2%9.8%8.4%
EPS (diluted)$2.12$2.64$2.13$2.04$6.49$8.08$4.50$5.55$2.20$2.07
Balance sheet
Cash and equivalents$359.3M$202.1M$163.1M$191.9M$387.1M$603.3M$454.4M$913.2M$1.16B$919.9M
Total assets$4.28B$6.09B$5.98B$6.54B$7.96B$15.0B$14.1B$13.6B$12.4B$12.2B
Total liabilities$2.12B$3.59B$3.39B$3.72B$4.22B$7.86B$6.75B$5.69B$4.73B$4.92B
Long-term debt$1.05B$1.79B$1.88B$2.06B$1.61B$4.98B$3.92B$3.18B$3.15B$2.63B
Shareholders' equity$2.15B$2.50B$2.58B$2.81B$3.74B$7.14B$7.38B$7.87B$7.67B$7.25B
Cash flow
Operating cash flow$350.6M$288.5M$311.0M$363.5M$892.2M$1.41B$679.8M$91.3M$628.3M$582.9M
Capital expenditure$31.7M$39.1M$93.3M$76.3M$63.6M$86.0M$85.6M$81.4M$86.6M$73.5M
Free cash flow$318.9M$249.4M$217.8M$287.1M$828.5M$1.32B$594.2M$9.90M$541.7M$509.4M
Dividends paid$30.8M$30.8M$31.0M$31.1M$31.2M$32.4M$35.3M$35.0M$34.5M$32.8M
Share buybacks$151.8M$3.83M$57.4M$6.31M$6.94M$73.1M$80.6M$388.9M$369.6M$820.8M

From Revvity's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Revvity vs the Health Care sector and the S&P 500

Revvity's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Revvity compared with the median Health Care company and the median S&P 500 company
MeasureRevvityHealth Care (59 other S&P 500 companies)S&P 500 (502 other companies)
Revenue growth, latest fiscal year+3.7%+7.2%+7.0%
Net margin, latest fiscal year8.4%13.1%13.0%
Dividend per share, latest fiscal year$0.28$2.48$2.40
Share price change, 1 year+58.4%+19.8%+5.6%

Revvity: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Revvity included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.

About Revvity

Revvity, Inc. is a multinational company headquartered in Waltham, Massachusetts, USA, in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.

Source: Wikipedia — Revvity

Headquarters
Waltham, Massachusetts From SEC filings, Oct 2026

Recent News (12)

More Health Care stocks

Browse all companies →